ZMB Member Sebastian Bauer
ZMB Member
Sebastian Bauer
Next ZMB-Member
Prof. Dr. Sebastian Bauer
West German Cancer Center (WTZ)
University Hospital Essen
Hufelandstr. 55
45147 Essen
- +49 201 723 2112
- Website
- Selected Publications
- Publication Metrics
-
- ZMB Research Program
Oncology
Research Overview
- Analysis of oncogenetic signalling pathways in soft-tissue sarcoma (esp. GIST)
- Evaluation of purposive, small molecular inhibitors of tyrosine kinases in soft-tissue sarcoma
- Development of soft-tissue sarcoma models (cell lines and Xenografts)
- Evaluation of preclinical diagnostic techniques/methods (in vitro/in vivo) for GIST and other soft-tissue sarcoma
Selected Publications
-
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations : Results from a Multi-institutional European Retrospective StudyIn: Clinical Cancer Research Vol. 28 (2022) Nr. 8, pp. 1672 - 1679
ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/ (Open Access) -
Gastrointestinal stromal tumours : ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 33 (2022) Nr. 1, pp. 20 - 33
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Prognostic Factors for Leiomyosarcoma with Isolated Metastases to the Lungs : Impact of MetastasectomyIn: Annals of Surgical Oncology Vol. 29 (2022) Nr. 7, pp. 4429 - 4436
ISSN: 1068-9265; 1534-4681Online Full Text: dx.doi.org/ (Open Access) -
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaIn: Clinical Cancer Research Vol. 28 (2022) Nr. 5, pp. 870 - 881
ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/ (Open Access) -
Bone sarcomas : ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-upIn: Annals of oncology Vol. 32 (2021) Nr. 12, pp. 1520 - 1536
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS StudyIn: Clinical Cancer Research Vol. 27 (2021) Nr. 23, pp. 6333 - 6342
ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersIn: Cancer Discovery Vol. 11 (2021) Nr. 11, pp. 2780 - 2795
ISSN: 2159-8290; 2159-8274Online Full Text: dx.doi.org/ -
Resistance to avapritinib in pdgfra-driven gist is caused by secondary mutations in the pdgfra kinase domainIn: Cancer Discovery Vol. 11 (2021) Nr. 1, pp. 108 - 125
ISSN: 2159-8290; 2159-8274Online Full Text: dx.doi.org/ -
Soft tissue and visceral sarcomas : ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆In: Annals of Oncology Vol. 32 (2021) Nr. 11,
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR) : A multicentre, open-label, phase 1 trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 7, pp. 935 - 946
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ -
Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST) : Analyses from INVICTUSIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 11535
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients with Metastatic Soft Tissue Sarcoma Age 60 Years or Older : Results of a German Intergroup StudyIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 30, pp. 3555 - 3564
ISSN: 1527-7755; 0732-183XOnline Full Text: dx.doi.org/ -
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS) : a double-blind, randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 7, pp. 923 - 934
ISSN: 1474-5488; 1470-2045Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST) : Analyses from INVICTUSIn: Journal of Clinical Oncology Vol. 38 (2020) Nr. 15_Suppl., pp. 11539
ISSN: 0732-183X; 1527-7755Online Full Text: dx.doi.org/ -
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-upIn: JAMA Oncology Vol. 6 (2020) Nr. 8, pp. 1241 - 1246
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ (Open Access) -
Defective homologous recombination DNA repair as therapeutic target in advanced chordomaIn: Nature Communications Vol. 10 (2019) Nr. 1, pp. 1635
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN) : a randomised phase 3 trialIn: The Lancet Vol. 394 (2019) Nr. 10197, pp. 478 - 487
ISSN: 1474-547X; 0140-6736Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3 : European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'In: Annals of Oncology Vol. 29 (2018) Nr. 3, pp. 758 - 765
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 4, pp. iv79 - iv95
ISSN: 0923-7534Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinibIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii584
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 4, pp. iv68 - iv78
ISSN: 0923-7534; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first lineIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii577
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Integrative genomic and transcriptomic analysis of leiomyosarcomaIn: Nature Communications Vol. 9 (2018) Nr. 1, pp. 144
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Soft tissue and visceral sarcomas : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 4, pp. iv51 - iv67
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical AdvancesIn: Annals of Oncology Vol. 29 (2018) Nr. 10, pp. 2037 - 2045
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
VOYAGER : An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)In: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii595
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumorsIn: Annals of Oncology Vol. 28 (2017) Nr. 3, pp. 541 - 546
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations : European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'In: Annals of Oncology Vol. 28 (2017) Nr. 12, pp. 3000 - 3008
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib : An exploratory analysis of a randomized clinical trialIn: JAMA Oncology Vol. 3 (2017) Nr. 5, pp. 602 - 609
ISSN: 2374-2445; 2374-2437Online Full Text: dx.doi.org/ Online Full Text (Open Access) -
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationIn: Nature Communications Vol. 8 (2017) pp. 14674
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Sustained mutant KIT activation in the Golgi complex is mediated by PKC-θ in gastrointestinal stromal tumorsIn: Clinical Cancer Research Vol. 23 (2017) Nr. 3, pp. 845 - 856
ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/ -
1401PD - Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMSIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. vi485
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumorsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 366PD
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib : Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)In: Annals of Surgical Oncology Vol. 23 (2016) Nr. 6, pp. 1924 - 1927
ISSN: 1068-9265; 1534-4681Online Full Text: dx.doi.org/ -
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trialIn: The lancet Vol. 387 (2016) Nr. 10028, pp. 1629 - 1637
ISSN: 0023-7507; 0140-6736Online Full Text: dx.doi.org/ -
Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFRIn: Angewandte Chemie International Edition Vol. 55 (2016) Nr. 36, pp. 10909 - 10912
ISSN: 0570-0833; 1521-3773Online Full Text: dx.doi.org/ -
Covalent-Allosteric Kinase InhibitorsIn: Angewandte Chemie International Edition Vol. 54 (2015) Nr. 35, pp. 10313 - 10316
ISSN: 0570-0833; 1521-3773; 1433-7851Online Full Text: dx.doi.org/ -
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas : subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072In: Annals of Oncology Vol. 25 (2014) Nr. 3, pp. 719 - 724
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ -
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsIn: Clinical Cancer Research Vol. 20 (2014) Nr. 22, pp. 5745 - 5755
ISSN: 1078-0432; 1557-3265Online Full Text: dx.doi.org/ -
Targeting glucose metabolism by 2-deoxyglucose in gastrointestinal stromal tumorsIn: Cancer Research Vol. 74 (2014) Nr. 19 Suppl.,
ISSN: 0008-5472; 1538-7445Online Full Text: dx.doi.org/ -
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal TumorsIn: Cancer Research Vol. 73 (2013) Nr. 12, pp. 3661 - 3670
ISSN: 0008-5472; 1538-7445Online Full Text: dx.doi.org/ -
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GISTIn: Cancer Research Vol. 73 (2013) Nr. Suppl. 8,
ISSN: 0008-5472; 1538-7445Online Full Text: dx.doi.org/ -
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trialIn: The Lancet Vol. 381 (2013) Nr. 9863, pp. 295 - 302
ISSN: 0140-6736; 1474-547XOnline Full Text: dx.doi.org/ -
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST) : The EORTC STBSG ExperienceIn: Annals of Surgical Oncology Vol. 20 (2013) Nr. 9, pp. 2937 - 2943
ISSN: 1068-9265; 1534-4681Online Full Text: dx.doi.org/ -
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor : a randomized trialIn: JAMA: Journal of the American Medical Association Vol. 307 (2012) Nr. 12, pp. 1265 - 1272
ISSN: 0098-7484; 1538-3598Online Full Text: dx.doi.org/ -
Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology Vol. 30 (2012) Nr. Suppl. 15, pp. 10032
ISSN: 0732-183X; 1527-7755 -
Rechallenge with ifosfamide-containing regimen as salvage option for patients with metastatic soft tissue sarcomas progressing after multiple pretreatmentsIn: Journal of Clinical Oncology Vol. 30 (2012) Nr. Suppl. 15,
ISSN: 0732-183X; 1527-7755 -
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsIn: Cancer Research Vol. 70 (2010) Nr. 1, pp. 150 - 159
ISSN: 0008-5472; 1538-7445; 0099-7013; 0099-7374Online Full Text: dx.doi.org/ -
Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-α and melphalan : Histologically characterized improved margins correlate with absence of recurrencesIn: Annals of Surgical Oncology Vol. 16 (2009) Nr. 3, pp. 676 - 686
ISSN: 1068-9265; 1534-4681Online Full Text: dx.doi.org/ -
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsIn: Cancer Research Vol. 69 (2009) Nr. 17, pp. 6941 - 6950
ISSN: 0008-5472; 1538-7445Online Full Text: dx.doi.org/ (Open Access)